Is there a role for the nuclear receptor PPARγ in neuropsychiatric diseases?
The aetiology of psychiatric diseases such as depression or schizophrenia remains largely unknown, even though multiple theories have been proposed. Although monoamine theory is the cornerstone of available pharmacological therapies, relapses, incomplete control of symptoms or failure in treatment occur frequently. From an inflammatory/immune point of view, both entities share several common hallmarks in their pathophysiology, e.g. neuroendocrine/immune alterations, structural/functional abnormalities in particular brain areas, and cognitive deficits, suggesting a dysregulated inflammatory-related component of these diseases that better explains the myriad of symptoms presented by affected individuals. In this review we aimed to explore the role and relevance of inflammatory related lipids (prostanoids) derived from arachidonic acid metabolism by identification of new inflammatory markers and possible pharmacological/dietary modulation of these compounds, with the aim of improving some of the symptoms developed by individuals affected with psychiatric diseases (a critical review of basic and clinical studies about inflammatory-related arachidonic acid metabolism on neuropsychiatric diseases is included). As a specific candidate, one of these immunoregulatory lipids, the anti-inflammatory prostaglandin 15d-PGJ₂ and its nuclear receptor peroxisome proliferator-activated nuclear receptor (PPARγ) could be used as a biological marker for psychiatric diseases. In addition, its pharmacological activation can be considered as a multi-faceted therapeutic target due to its anti-inflammatory/antioxidant/anti-excitotoxic/pro-energetic profile, reported in some inflammatory-related scenarios (neurological and stress-related diseases). PPARs are activated by a great variety of compounds, the most relevant being the currently prescribed group of anti-diabetic drugs thiazolidinediones, and some cannabinoids (both endocannabinoids, phytocannabinoids or synthetic), as possible novel therapeutical strategy.
García-Bueno
Borja
B
Departamento de Farmacología, Facultad de Medicina, Universidad Complutense, Centro de Investigación en red de Salud Mental, CIBERSAM-ISCIII, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain. bgbueno@med.ucm.es
Pérez-Nievas
Beatriz G
BG
Leza
Juan C
JC
D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D001523:Mental Disorders / Q000188:drug therapy*; D009474:Neurons / Q000378:metabolism; D047495:PPAR gamma / Q000378:metabolism*; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism; D012559:Schizophrenia / Q000188:drug therapy
D047495:PPAR gamma; D018160:Receptors, Cytoplasmic and Nuclear